Previous attempts were made to develop ABC transporter inhibitors for clinical use to overcome MDR, but they failed in clinical trials primarily because the trials did not limit the patient selection to those whose tumours were nonresponsive to treatment due to ABC transporter overexpression. This evidence concerns the gene ABCG2 and neoplasm.